Logo image of OMER

OMEROS CORP (OMER) Stock Fundamental Analysis

NASDAQ:OMER - US6821431029 - Common Stock

4.305 USD
-0.04 (-1.03%)
Last: 8/26/2025, 12:02:38 PM
Fundamental Rating

0

Taking everything into account, OMER scores 0 out of 10 in our fundamental rating. OMER was compared to 193 industry peers in the Pharmaceuticals industry. OMER has a bad profitability rating. Also its financial health evaluation is rather negative. OMER is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year OMER has reported negative net income.
In the past year OMER has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: OMER reported negative net income in multiple years.
OMER had negative operating cash flow in 4 of the past 5 years.
OMER Yearly Net Income VS EBIT VS OCF VS FCFOMER Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

1.2 Ratios

With a Return On Assets value of -61.06%, OMER is not doing good in the industry: 65.28% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -61.06%
ROE N/A
ROIC N/A
ROA(3y)-26.61%
ROA(5y)-21.96%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OMER Yearly ROA, ROE, ROICOMER Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K 1.5K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for OMER so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OMER Yearly Profit, Operating, Gross MarginsOMER Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

0

2. Health

2.1 Basic Checks

Compared to 1 year ago, OMER has less shares outstanding
OMER has more shares outstanding than it did 5 years ago.
OMER has a worse debt/assets ratio than last year.
OMER Yearly Shares OutstandingOMER Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
OMER Yearly Total Debt VS Total AssetsOMER Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

Based on the Altman-Z score of -8.72, we must say that OMER is in the distress zone and has some risk of bankruptcy.
OMER's Altman-Z score of -8.72 is on the low side compared to the rest of the industry. OMER is outperformed by 66.32% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -8.72
ROIC/WACCN/A
WACCN/A
OMER Yearly LT Debt VS Equity VS FCFOMER Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 0.81 indicates that OMER may have some problems paying its short term obligations.
OMER has a Current ratio of 0.81. This is amonst the worse of the industry: OMER underperforms 86.53% of its industry peers.
OMER has a Quick Ratio of 0.81. This is a bad value and indicates that OMER is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of OMER (0.81) is worse than 79.27% of its industry peers.
Industry RankSector Rank
Current Ratio 0.81
Quick Ratio 0.81
OMER Yearly Current Assets VS Current LiabilitesOMER Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 10.21% over the past year.
EPS 1Y (TTM)10.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 27.97% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y28.41%
EPS Next 2Y40.45%
EPS Next 3Y28.8%
EPS Next 5Y27.97%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
OMER Yearly Revenue VS EstimatesOMER Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
OMER Yearly EPS VS EstimatesOMER Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 4 6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

OMER reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OMER. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OMER Price Earnings VS Forward Price EarningsOMER Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OMER Per share dataOMER EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -1 -2 -3

4.3 Compensation for Growth

A more expensive valuation may be justified as OMER's earnings are expected to grow with 28.80% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.45%
EPS Next 3Y28.8%

More info and screens

0

5. Dividend

5.1 Amount

OMER does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

OMEROS CORP

NASDAQ:OMER (8/26/2025, 12:02:38 PM)

4.305

-0.04 (-1.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-14 2025-08-14/amc
Earnings (Next)11-11 2025-11-11
Inst Owners41.14%
Inst Owner Change5.46%
Ins Owners3.82%
Ins Owner Change0%
Market Cap293.00M
Analysts80
Price Target30.6 (610.8%)
Short Float %19.8%
Short Ratio10.72
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)6.01%
Min EPS beat(2)-0.35%
Max EPS beat(2)12.36%
EPS beat(4)3
Avg EPS beat(4)16.47%
Min EPS beat(4)-0.35%
Max EPS beat(4)31.91%
EPS beat(8)6
Avg EPS beat(8)19.22%
EPS beat(12)9
Avg EPS beat(12)55.32%
EPS beat(16)12
Avg EPS beat(16)46.64%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-25.93%
EPS NQ rev (1m)-11.43%
EPS NQ rev (3m)N/A
EPS NY rev (1m)1.02%
EPS NY rev (3m)12%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-61.54%
Revenue NY rev (3m)-79.17%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.11
EYN/A
EPS(NY)-0.07
Fwd EYN/A
FCF(TTM)-1.74
FCFYN/A
OCF(TTM)-1.74
OCFYN/A
SpS0
BVpS-3.36
TBVpS-3.36
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -61.06%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-26.61%
ROA(5y)-21.96%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 7.68%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.81
Quick Ratio 0.81
Altman-Z -8.72
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)25.18%
Cap/Depr(5y)22.56%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)10.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55.67%
EPS Next Y28.41%
EPS Next 2Y40.45%
EPS Next 3Y28.8%
EPS Next 5Y27.97%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y25.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year75.27%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-231.71%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-231.21%
OCF growth 3YN/A
OCF growth 5YN/A